CytRx Announces That FDA Lifts Clinical Hold Of Arimoclomol In ALS

Main Category: Muscular Dystrophy / ALS Also Included In: Clinical Trials / Drug Trials Article Date: 04 Dec 2009 CytRx Corporation , a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis , following...